Limitations in activities of daily living at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in participation at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects requiring withdrawal/discontinuation of study medication · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as adverse events requiring withdrawal of… compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in motor nerve function at 1 year · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in nerve pain and in nerve tenderness at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in activities of daily living at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in participation at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as: occurrence of one or more major adverse… compared with placebo (moderate certainty).
1 finding from 1 review
1Small sample size. · people with nerve damage (< 6 months' duration) in leprosy
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Improvement in sensory nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in improvement in sensory nerve function at 1 year compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in motor nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy
1 finding from 1 review
Proportion of patients with clinical improvement in function compared to baseline · patients with ulnar neuropathy at the elbow
Simple decompression showed no clear difference in proportion of participants with clinical improvement in function… compared with transposition (moderate certainty).
1 finding from 1 review
Proportion of patients with clinical improvement in function compared to baseline ‐ simple decompression versus subcutaneous transposition · patients with ulnar neuropathy at the elbow
Simple decompression showed no clear difference in subgroup: proportion of participants with clinical improvement in… compared with transposition (moderate certainty).
1 finding from 1 review
Subgroup: proportion of participants with clinical improvement in function compared to baseline ‐ simple decompression versus submuscular transposition · patients with ulnar neuropathy at the elbow
Simple decompression showed no clear difference in subgroup: proportion of participants with clinical improvement in… compared with transposition (moderate certainty).
1 finding from 1 review
Wound infection · patients with ulnar neuropathy at the elbow
Simple decompression probably leads to lower adverse events: proportion of participants with deep/superficial… compared with transposition (moderate certainty).
1 finding from 1 review
Ataxia rating score ICARS; range 0 to 100) · people with Friedreich ataxia
1 finding from 1 review
Ejection fraction · people with Friedreich ataxia
1 finding from 1 review
End‐diastolic interventricular septal thickness (IVSTd) Measured in mm · people with Friedreich ataxia
1 finding from 1 review
Left ventricular mass · people with Friedreich ataxia
1 finding from 1 review
Survival (not measured) · people with Friedreich ataxia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found